HALO for Pediatric Obesity
Phase-Based Progress Estimates
Effectiveness
Safety
Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Pediatric Obesity+1 More
HALO - BehavioralEligibility
Any Age
Female
What conditions do you have?
Select
Eligibility
Any Age
Female
What conditions do you have?
Select
Study Summary
This is the Phase 2 pilot/feasibility randomized controlled trial of HALO (Health And Lifestyle Behaviors In Offspring), a parent-led behavioral intervention targeting a high-risk pediatric population (i.e., residing offspring ages 6-12; body mass index > the 70th and < 120% of the 95th percentiles of mothers with severe obesity) that is uniquely well-timed, when mothers are highly engaged in behavior change and losing weight during the first year following bariatric surgery.
Eligible Conditions
- Pediatric Obesity
- Obesity
Treatment Effectiveness
Effectiveness Progress
Other trials for Pediatric Obesity
Study Objectives
2 Primary · 12 Secondary · Reporting Duration: baseline to 26 weeks (post-treatment) and 52 weeks (6-month follow-up)
Week 26
Change in child emotional functioning from baseline to 26 weeks (post-treatment) using Sizing Me Up
Change in maternal percent weight loss and body mass index from baseline to 26 weeks (post-treatment)
Change in maternal total kcals from baseline to 26 weeks (post-treatment) using a 3-day dietary recall
Change in mother's minutes of moderate to vigorous physical activity from baseline to 26 weeks (post-treatment)
Implementation - Fidelity
Implementation - Usability/Satisfaction
Preliminary Efficacy - Change in child body mass index standardized for age/sex from baseline to 26 weeks (post-treatment)
Secondary - Change in child daily intake of total kcals, and kcals from red foods, sugar-sweetened beverages, and fruits and vegetables from baseline to 26 weeks (post-treatment) using a 3-day dietary recall
Secondary - Change in child hours of screen time from baseline to 26 weeks (post-treatment)
Secondary - Change in child minutes of moderate to vigorous physical activity (MVPA) from baseline to 26 weeks (post-treatment)
Secondary - Change in mother use of encouragement/modeling from baseline to 26 weeks (post-treatment)
Secondary - Change in mother-reported child feeding practices of restriction, pressure to eat, perceived responsibility, and monitoring from baseline to 26 weeks (post-treatment)
Secondary - Change in physical home food environment total kcals, and kcals from sugar-sweetened beverages, snack foods, fruits, and vegetables from baseline to 26 weeks (post-treatment)
Time needed for intervention
Week 52
Attendance/Participation rates
Week 52
Change in child emotional functioning from baseline to 52 weeks (6-month follow-up) using Sizing Me Up
Change in maternal percent weight loss and body mass index from baseline to 52 weeks (6-month follow-up)
Change in maternal total kcals from baseline to 52 weeks (6-month follow-up) using a 3-day dietary recall
Change in mother's minutes of moderate to vigorous physical activity from baseline to 52 weeks (6-month follow-up)
Preliminary Efficacy - Change in child body mass index standardized for age/sex from baseline to 52 weeks (6-month follow-up)
Secondary - Change in child daily intake of total kcals, and kcals from red foods, sugar-sweetened beverages, and fruits and vegetables from baseline to 52 weeks (6-month follow-up) using a 3-day dietary recall
Secondary - Change in child hours of screen time from baseline to 52 weeks (6-month follow-up)
Secondary - Change in child minutes of moderate to vigorous physical activity (MVPA) from baseline to 52 weeks (6-month follow-up)
Secondary - Change in mother use of encouragement/modeling from baseline to 52 weeks (6-month follow-up)
Secondary - Change in mother-reported child feeding practices of restriction, pressure to eat, perceived responsibility, and monitoring from baseline to 52 weeks (6-month follow-up)
Secondary - Change in physical home food environment total kcals, and kcals from sugar-sweetened beverages, snack foods, fruits, and vegetables from baseline to 52 weeks (6-month follow-up)
Trial Safety
Safety Progress
Other trials for Pediatric Obesity
Trial Design
2 Treatment Groups
Enhanced Standard of Care
1 of 2
Treatment
1 of 2
Active Control
Experimental Treatment
50 Total Participants · 2 Treatment Groups
Primary Treatment: HALO · No Placebo Group · N/A
Treatment
Behavioral
Experimental Group · 1 Intervention: HALO · Intervention Types: BehavioralEnhanced Standard of Care
Behavioral
ActiveComparator Group · 1 Intervention: Enhanced Standard of Care · Intervention Types: BehavioralTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HALO
2016
N/A
~60
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to 26 weeks (post-treatment) and 52 weeks (6-month follow-up)
Closest Location: Cincinnati Children's Hospital Medical Center · Cincinnati, OH
2011First Recorded Clinical Trial
6 TrialsResearching Pediatric Obesity
713 CompletedClinical Trials
Who is running the clinical trial?
Children's Hospital Medical Center, CincinnatiLead Sponsor
736 Previous Clinical Trials
5,414,787 Total Patients Enrolled
6 Trials studying Pediatric Obesity
15,370 Patients Enrolled for Pediatric Obesity
University of DelawareOTHER
130 Previous Clinical Trials
36,400 Total Patients Enrolled
3 Trials studying Pediatric Obesity
143 Patients Enrolled for Pediatric Obesity
Margaret H Zeller, PhDPrincipal InvestigatorCincinnati Chidren's Hospital Medical Center
Eligibility Criteria
Age Any Age · Female Participants · 8 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:The caregiver is aged 3-12 months post undergoing a non-device based bariatric surgical procedure.
You are able to read, write, and speak in English.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments